LCM Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

LCM Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$517K	Buy	1,158 +23	+2%	+$10.7K	0.26%	50
2025 Q4	$515K	Sell	1,135 -10	-0.9%	-$4.31K	0.25%	47
2025 Q3	$448K	Sell	1,145 -3	-0.3%	-$1.25K	0.22%	53
2025 Q2	$511K	Buy	1,148 +4	+0.3%	+$1.84K	0.27%	50
2025 Q1	$555K	Buy	1,144 +71	+7%	+$33.1K	0.33%	47
2024 Q4	$432K	Buy	1,073 +19	+2%	+$8.81K	0.24%	55
2024 Q3	$490K	Buy	1,054 +58	+6%	+$27.9K	0.28%	51
2024 Q2	$467K	Buy	996 +56	+6%	+$24.3K	0.29%	49
2024 Q1	$393K	Buy	940 +14	+2%	+$5.92K	0.25%	55
2023 Q4	$377K	Buy	926 +16	+2%	+$5.91K	0.27%	55
2023 Q3	$316K	Buy	910 +113	+14%	+$39.5K	0.26%	57
2023 Q2	$280K	Buy	797 +39	+5%	+$13.1K	0.23%	67
2023 Q1	$239K	Buy	+758	New	+$227K	0.21%	74

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

LCM Capital Management's VRTX Position: Q1 2026 in Review

LCM Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 2% in Q1 2026, buying an estimated $10.7K and bringing the position to 1,158 shares worth $517K. The position accounts for 0.26% of the portfolio, ranked #50.

LCM Capital Management first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $555K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

LCM Capital Management held 1,158 shares of Vertex Pharmaceuticals worth $517K as of Q1 2026.
LCM Capital Management bought 23 Vertex Pharmaceuticals shares in Q1 2026, an estimated $10.7K.
Vertex Pharmaceuticals made up 0.26% of LCM Capital Management's portfolio in Q1 2026, its #50 holding.
LCM Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
LCM Capital Management's Vertex Pharmaceuticals position peaked at $555K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on LCM Capital Management's 13F filing for Q1 2026, filed 21 Apr 2026.